NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVEO stock has increased by 22.6% and is now trading at $4.28. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AVEO Pharmaceuticals.

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for AVEO Pharmaceuticals.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.31. The biopharmaceutical company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $2.10 million. AVEO Pharmaceuticals had a return on equity of 225.40% and a net margin of 32.60%. View AVEO Pharmaceuticals' earnings history.

AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

2 equities research analysts have issued twelve-month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $4.00 to $20.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 180.4% from the stock's current price. View analysts' price targets for AVEO Pharmaceuticals.

Headlines about AVEO stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAVEO Pharmaceuticals.

AVEO Pharmaceuticals saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 1,503,500 shares, a decline of 7.8% from the February 27th total of 1,630,000 shares. Based on an average daily trading volume, of 188,800 shares, the days-to-cover ratio is presently 8.0 days. Approximately 11.2% of the shares of the stock are sold short. View AVEO Pharmaceuticals' Current Options Chain.

Some companies that are related to AVEO Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Advanced Micro Devices (AMD), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Alibaba Group (BABA), Opko Health (OPK), Bellicum Pharmaceuticals (BLCM) and Canopy Growth (CGC).

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

AVEO Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Jacobs Levy Equity Management Inc. (0.90%), Geode Capital Management LLC (0.61%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View institutional ownership trends for AVEO Pharmaceuticals.

AVEO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for AVEO Pharmaceuticals.

AVEO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP, and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini, and Ravi Viswanathan. View insider buying and selling activity for AVEO Pharmaceuticals.

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVEO stock can currently be purchased for approximately $4.28.

AVEO Pharmaceuticals has a market capitalization of $68.82 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe. View additional information about AVEO Pharmaceuticals.

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]